Target intelligence / Profile preview

CYLD antisense RNA 1 (CYLD-AS1)

Target
CYLD-AS1
Molecular classification
Long non-coding RNA (lncRNA), Natural antisense transcript, Non-coding RNA
01

Overview

CYLD antisense RNA 1 (CYLD-AS1) is a long non-coding RNA gene that is transcribed in the antisense orientation relative to the protein-coding CYLD gene. As a natural antisense transcript, CYLD-AS1 can modulate the expression of CYLD, which encodes a deubiquitinase enzyme and a tumor suppressor implicated in the regulation of NF-κB signaling and cell cycle control[7][8]. CYLD-AS1 expression is upregulated in certain conditions, such as oxidative stress in retinal pigment epithelial cells, where its depletion can lead to increased cell proliferation and changes in mitochondrial dynamics, suggesting a role in tissue homeostasis and disease processes, such as age-related macular degeneration[8]. Antisense lncRNAs like CYLD-AS1 may act through mechanisms that include RNA interference, epigenetic modification, or modulation of mRNA stability or translation, but CYLD-AS1 is not a classic druggable target at present and there are no pharmacological agents that specifically interact with it[7][8][3].

Other names
CYLD-AS1
02

Biological functions

Regulation of gene expression (in cis or trans, typically affecting CYLD and possibly other target RNAs)Modulation of cell proliferation and apoptosis (shown in specific contexts, e.g., retinal pigment epithelial cells[8])Regulation during stress conditions (such as oxidative stress[8])
03

Disease associations

Age-related macular degeneration (by modulating retinal pigment epithelial cell behavior under oxidative stress[8])Potential involvement in inflammatory or autoimmune diseases (linked in some gene databases to Yao syndrome and Blau syndrome, though mechanistic evidence is limited[7])

Beyond the preview

Go deeper on CYLD antisense RNA 1 (CYLD-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CYLD antisense RNA 1 (CYLD-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call